Download Read Complete CV.

1
CURRICULUM VITAE
Jacques Henri Edmond Grosset, MD
DEMOGRAPHIC INFORMATION
Current Appointments :
- Emeritus Professor of Bactériologie-Virologie-Hygiène, Faculty of Medicine Pitié Salpêtrière,
University Pierre and Mary Curie, Paris VI
- Visiting Professor, Center for Tuberculosis Research, Johns Hopkins School of Medicine,
Personal Data
Date of birth:
Citizenship:
Marital Status:
Home address:
500 W. University Parkway, Apt14C
Baltimore, MD 21210-3299
Tel: 410-889-6247.
September 16, 1929
French
Married, 1957. 4 children born: 1959, 1960, 1962, 1966
Business Address:
Center for Tuberculosis Research
Dept. of Medicine, Div. of Infectious Diseases
Johns Hopkins School of Medicine
424 N. Bond Street
Baltimore, MD 21231
Tel: 410-955-3507
Fax: 410-614-8173
E-mail: [email protected]
Education and Training:
Baccalaureate.
Medical studies.
M.D.
Internal Med. Residency
1947
1947-1954
1956
1955-1959
Pasteur Institute Fellow
1955-1956
Medical Licensure
1956
Diplomate Bact. & Vir.
1956
Diplomate Immunology
1956
Certified Prof. of Bact. Vir. Parasit.
1965
Lille University, France
Lille University , Faculty of Medicine
Paris University
Foundation Sanatorium Etudiants de France
Medical Director: Dr René Cohen
Paris
Paris University
Paris University
National Board of Microbiology
Professional experience:
Assistant, Department of Tuberculosis (Head Dr. Georges Canetti)
Pasteur Institute, Paris, France
Chief of Laboratory, Head of the Mycobacteria Department
Pasteur Institute, Algiers, Algeria
Professor of Bacteriology and Virology,
Faculty of Medicine, Algiers, Algeria
Professor of Bacteriology, Virology, and Hygiene
Faculty of Medicine Pitié-Salpêtrière, Paris, France
Emeritus Professor of Bacteriology, Virology, and Hygiene,
Faculty of Medicine Pitié Salpêtrière
Visiting Professor, Center for Tuberculosis Research
Johns Hopkins School of Medicine
1956 - 1963
1963 – 1970
1966 - 1970
1970 – 1999
1999- present
01/02 – present
2
Affiliations
Foundation Sanatorium Etudiants de France, 1956-1959
Post-cure, Rue du Conventionel Chiappe, Paris
Physician responsible for the tuberculosis laboratory,
Pasteur Institute, Algiers
Physician responsible for BCG vaccination,
Pasteur Institute, Algiers
Deputy Director Central Laboratory for Bacteriology and Virology
Pitie-Salpetriere University Hospital, Paris
Director Central Laboratory for Bacteriology and Virology
Pitie-Salpetriere University Hospital, Paris
Consulting Professor in the pneumology department
Pitié Salpêtrière Hospital, Paris
Physician coordinator of tuberculosis control among homeless,
Social Emergency Unit (Samu Social), Paris, France
1963-1970
1966-1970
1970-1977
1977-1996
1996-1999
1999 - 2001
RESEARCH ACTIVITIES
Publications:
Journal articles (peer-reviewed)
Year 2004
Nuermberger EL, T. Yoshimatsu, S. Tyagi, WR Bishai, and JH Grosset. 2004. Paucibacillary
tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect. Immun. In
press
Nuermberger EL, T. Yoshimatsu, S. Tyagi, RJ O’Brien, AN Vernon, RE Chaisson, WR Bishai, and JH
Grosset. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine
tuberculosis. Am J Respir Crit Care Med. In press
Year 2003
Emmanuelli X, J Grosset. 2003. Tuberculose et pauvreté. Rev Mal Respir 20: 1-3.
Ginsburg AS, JH Grosset, and WR Bishai. 2003. Fluoroquinolones, tuberculosis, and resistance. The
Lancet Infectious Diseases 3: 432-442.
Grosset J. 2003. Mycobacterium tuberculosis in the extracellular compartment: an underestimated
adversary. Antimicrob. Agents Chemother. 47: 833-836.
Lamichane G, M. Zignol, NJ Blades, DE Geiman, A Dougherty, J Grosset, KW Broman, and WR
Bishai. 2003. A postgenomic method for predicting essential genes at subsaturation levels of
mutagenesis: application to Mycobacterium tuberculosis. PNAS 100: 7213-7218.
Lounis N., C. Maslo, C. Truffot-Pernot, J. Grosset, RJ Boelaert. 2003. Impact of iron loading on the
activity of isoniazid or ethambutol in the treatment of murine tuberculosis. Int J Tuberc Lung Dis. 7:
575-12.
Quy HTW, NTN.Lan, MW. Borgdorff, J. Grosset, PD Linh, LB. Tung, D. van Soolingen, M. Raviglione,
NV Cô, J. Broekmans.2003. Drug resistance among failure and relapse cases of tuberculosis: is the
standard re-treatment regimen adequate? Int J Tuberc Lung Dis. 7: 631-636.
Robert J, D Trystram, C Truffot, J Grosset. 2003. La multiresistance (MDR) de Mycobacterium
tuberculosis aux antibiotiques en France depuis 1992. Med Mal Infect. 33 (S3): 183s-187s.
3
Year 2002
Dega, H., A. Bentoucha, J. Robert, V. Jarlier, and J. Grosset. 2002. Bactericidal activity of the
combination rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents
Chemother.46:3193-3196.
Grosset, J., L. Zunic, and C. Morcrette. 2002. [World epidemiology of tuberculosis and resistance
against anti-tuberculosis drugs]. Ann Med Interne (Paris). 153:107-12.
Yoshimatsu, T., E. Nuermberger, S. Tyagi, R. Chaisson, W. Bishai, and J. Grosset. 2002. Bactericidal
activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents
Chemother. 46:1875-1879.
Year 2001
Astagneau, P., N. Desplaces, V. Vincent, V. Chicheportiche, A. Botherel, S. Maugat, K. Lebascle, P.
Leonard, J. Desenclos, J. Grosset, J. Ziza, and G. Brucker. 2001. Mycobacterium xenopi spinal
infections after discovertebral surgery: investigation and screening of a large outbreak. Lancet.
358:747-51
Bentoucha, A., J. Robert, H. Dega, N. Lounis, V. Jarlier, and J. Grosset. 2001. Activities of new
macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents
Chemother. 45:3109-12
Boelaert, J. R., R. Appelberg, M. S. Gomes, E. Blasi, R. Mazzolla, J. Grosset, N. Lounis, K.
Soteriadou, M. Thiakaki, D. Taramelli, and C. Tognazioli. 2001. Experimental results on chloroquine
and AIDS-related opportunistic infections. J Acquir Immune Defic Syndr. 26:300-1.
Grosset, J. H. 2001. Newer drugs in leprosy. Int J Lepr Other Mycobact Dis. 69:S14-8.
Grosset, J. H., and S. T. Cole. 2001. Genomics and the chemotherapy of leprosy. Lepr Rev. 72:42940.
Honore, N., P. W. Roche, J. H. Grosset, and S. T. Cole. 2001. A method for rapid detection of
rifampicin-resistant isolates of Mycobacterium leprae. Lepr Rev. 72:441-8.
Lounis, N., A. Bentoucha, C. Truffot-Pernot, B. Ji, R. J. O'Brien, A. Vernon, G. Roscigno, and J.
Grosset. 2001. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against
Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother. 45:3482-6.
Lounis, N., C. Truffot-Pernot, A. Bentoucha, J. Robert, B. Ji, and J. Grosset. 2001. Efficacies of
clarithromycin regimens against Mycobacterium xenopi in mice. Antimicrob Agents Chemother.
45:3229-30.
Lounis, N., C. Truffot-Pernot, J. Grosset, V. R. Gordeuk, and J. R. Boelaert. 2001. Iron and
Mycobacterium tuberculosis infection. J Clin Virol. 20:123-6.
Year 2000
Cambau, E., C. Truffot-Pernot, F. Boulahbal, C. Wichlacz, J. Grosset, and V. Jarlier. 2000.
Mycobacterial growth indicator tube versus the proportion method on Lowenstein-Jensen medium for
antibiotic susceptibility testing of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis. 19:93842.
Consigny, S., A. Bentoucha, P. Bonnafous, J. Grosset, and B. Ji. 2000. Bactericidal activities of HMR
3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrob Agents
Chemother. 44:2919-21.
4
Daniel, N., N. Lounis, B. Ji, R. J. O'Brien, A. Vernon, L. J. Geiter, M. Szpytma, C. Truffot-Pernot, G.
Hejblum, and J. Grosset. 2000. Antituberculosis activity of once-weekly rifapentine-containing
regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens. Am J Respir Crit
Care Med. 161:1572-7.
Dega, H., O. Chosidow, S. Barete, B. Carbonnelle, J. Grosset, and V. Jarlier. 2000. [Mycobacterium
ulcerans infection]. Ann Med Interne (Paris). 151:339-44.
Dega, H., J. Robert, P. Bonnafous, V. Jarlier, and J. Grosset. 2000. Activities of several antimicrobials
against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother. 44:2367-72.
Grosset, J. 2000. The new challenges for chemotherapy research. Lepr Rev. 71:S100-4.
Ji, B., and J. Grosset. 2000. Combination of rifapentine-moxifloxacin-minocycline (PMM) for the
treatment of leprosy. Lepr Rev. 71:S81-7.
Nguyen, L. N., J. L. Cartel, and J. H. Grosset. 2000. Chemoprophylaxis of leprosy in the southern
Marquesas with a single 25 mg/kg dose of rifampicin. Results after 10 years. Lepr Rev. 71:S33-5;
discussion S35-6.
Robert, J., D. Trystram, C. Truffot-Pernot, E. Cambau, V. Jarlier, and J. Grosset. 2000. Twenty-five
years of tuberculosis in a French university hospital: a laboratory perspective. Int J Tuberc Lung Dis.
4:504-12.
Robert, J., D. Trystram, C. Truffot-Pernot, B. Carbonnelle, and J. Grosset. 2000. Surveillance of
Mycobacterium tuberculosis drug resistance in France, 1995-1997. AZAY Mycobacteria Study Group.
Int J Tuberc Lung Dis. 4:665-72.
Year 1999
Flament-Saillour, M., J. Robert, V. Jarlier, and J. Grosset. 1999. Outcome of multi-drug-resistant
tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med. 160:587-93.
Grosset J. 1999. A national survey of human Mycobacterium bovis infection in France. Network of
Microbiology Laboratories in France. Int J Tuberc Lung Dis. 3:711-4.
Grosset, J. 1999. [Which strategies for eradication of tuberculosis?]. Bull Acad Natl Med. 183:25-37;
discussion 37-40.
Grosset, J. 1999. [Leprosy and tuberculosis: opposite results?]. Med Trop (Mars). 59:25-30.
71. 72.
Grosset J. Systematic drug susceptibility testing : a necessary component of the "DOT Plus"
strategy? Int. Tuberc. Lung Dis. 1999; 3 : 549-550.
Lounis, N., C. Truffot-Pernot, R. G. Ridley, G. Alber, and J. H. Grosset. 1999. Impacts of interleukin12 on multiplication of Mycobacterium tuberculosis and Mycobacterium avium complex in mice. Clin
Microbiol Infect. 5:331-338.
Rinder, H., K. Feldmann, E. Tortoli, J. Grosset, M. Casal, E. Richter, M. Rifai, V. Jarlier, M. Vaquero,
S. Rusch-Gerdes, E. Cambau, J. Gutierrez, and T. Loscher. 1999. Culture-independent prediction of
isoniazid resistance in Mycobacterium tuberculosis by katG gene analysis directly from sputum
samples. Mol Diagn. 4:145-52.
Robert, J., F. Boulahbal, D. Trystram, C. Truffot-Pernot, A. C. de Benoist, V. Vincent, V. Jarlier, and J.
Ji, B., and J. H. Grosset. 1999. Drugs and regimens for preventive therapy against tuberculosis,
disseminated Mycobacterium avium complex infection and leprosy. Int J Lepr Other Mycobact Dis.
67:S45-55
Year 1998
5
Carbonne, A., N. Lemaitre, M. Bochet, C. Truffot-Pernot, C. Katlama, J. Grosset, F. Bricaire, and V.
Jarlier. 1998. Mycobacterium avium complex common-source or cross-infection in AIDS patients
attending the same day-care facility. Infect Control Hosp Epidemiol. 19:784-6.
Craft, J. C., G. F. Notario, J. H. Grosset, and L. B. Heifets. 1998. Clarithromycin resistance and
susceptibility patterns of Mycobacterium avium strains isolated during prophylaxis for disseminated
infection in patients with AIDS. Clin Infect Dis. 27:807-12.
Grosset, J. H., and S. Franzblau. 1998. Report of workshop on chemotherapy. Int J Lepr Other
Mycobact Dis. 66:595-6.
Grosset, J. 1998. [What's new for tuberculosis in 1998?]. Rev Med Interne. 19:613-6.
Grosset, J., N. Lounis, C. Truffot-Pernot, R. J. O'Brien, M. C. Raviglione, and B. Ji. 1998. Onceweekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am J Respir Crit Care
Med. 157:1436-40.
Grosset, J., and C. Truffot-Pernot. 1998. [Mycobacterium xenopi, a newcomer?]. Rev Prat. 48:701-3.
Ji, B., S. Sow, E. Perani, C. Lienhardt, V. Diderot, and J. Grosset. 1998. Bactericidal activity of a
single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium
leprae in mice and in lepromatous patients. Antimicrob Agents Chemother. 42:1115-20.
Ji, B., N. Lounis, C. Maslo, C. Truffot-Pernot, P. Bonnafous, and J. Grosset. 1998. In vitro and in vivo
activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents
Chemother. 42:2066-9.
Jouveshomme, S., E. Cambau, D. Trystram, M. Szpytma, W. Sougakoff, J. P. Derenne, and J.
Grosset. 1998. Clinical utility of an amplification test based on ligase chain reaction in pulmonary
tuberculosis. Am J Respir Crit Care Med. 158:1096-101.
Lemaitre, N., W. Sougakoff, C. Truffot-Pernot, E. Cambau, J. P. Derenne, F. Bricaire, J. Grosset, and
V. Jarlier. 1998. Use of DNA fingerprinting for primary surveillance of nosocomial tuberculosis in a
large urban hospital: detection of outbreaks in homeless people and migrant workers. Int J Tuberc
Lung Dis. 2:390-6.
Schwoebel, V., B. Decludt, A. C. de Benoist, S. Haeghebaert, G. Torrea, V. Vincent, and J. Grosset.
1998. Multidrug resistant tuberculosis in France 1992-4: two case-control studies. British.Medical.J.
317:630-1.
Year 1997
Dautzenberg, B., C. Truffot-Pernot, J. Hazebroucq, S. Legris, C. Guerin, C. Begelman, G.
Guermonprez, M. H. Fievet, C. Chastang, and J. Grosset. 1997. A randomized comparison of two
clarithromycin doses for treatment of Mycobacterium avium complex infections. Infection. 25:16-21.
Gimenez, F., V. Leblond, J. Nguyen, P. Serrand, J. L. Binet, J. Grosset, and A. Thuillier. 1997.
Variations of teicoplanin concentrations in neutropenic patients. J Clin Pharm Ther. 22:187-90.
Grosset, J., and B. Ji. 1997. Prevention of the selection of clarithromycin-resistant Mycobacterium
avium-intracellulare complex. Drugs. 54:23-7; discussion 28-9.
Grosset, J. 1997. Whither short-course chemotherapy for leprosy? Indian J Lepr. 69:119-20.
Iborra, C., E. Cambau, C. Lecomte, J. Grosset, F. Bricaire, and E. Caumes. 1997. [Cutaneous
tuberculosis. A study of 4 cases]. Ann Dermatol Venereol. 124:139-43.
6
Ji, B., P. Jamet, S. Sow, E. G. Perani, I. Traore, and J. H. Grosset. 1997. High relapse rate among
lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks. Antimicrob Agents
Chemother. 41:1953-6
Lounis, N., B. Ji, C. Truffot-Pernot, and J. Grosset. 1997. Which aminoglycoside or fluoroquinolone is
more active against Mycobacterium tuberculosis in mice? Antimicrob Agents Chemother. 41:607-10.
Lounis, N., B. Ji, C. Truffot-Pernot, and J. Grosset. 1997. Comparative activities of amikacin against
Mycobacterium avium complex in nude and beige mice. Antimicrob Agents Chemother. 41:1168-9.
Mane, I., J. L. Cartel, and J. H. Grosset. 1997. Field trial on efficacy of supervised monthly dose of
600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
Int J Lepr Other Mycobact Dis. 65:224-9.
May, T., F. Brel, C. Beuscart, V. Vincent, C. Perronne, T. Doco-Lecompte, T. Saint-Marc, B.
Dautzenberg, and J. Grosset. 1997. Comparison of combination therapy regimens for treatment of
human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium
avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida. Clin Infect Dis.
25:621-9.
Wyplosz, B., C. Truffot-Pernot, J. Robert, V. Jarlier, and J. Grosset. 1997. [The bacteriology of
tuberculosis and non-tuberculosis mycobacterial infections]. Rev Mal Respir. 14:S33-48.
Year 1996
Doucet-Populaire, F., V. Lalande, E. Carpentier, A. Bourgoin, M. Dailloux, C. Bollet, A. Vachee, D.
Moinard, J. Texier-Maugein, B. Carbonnelle, and J. Grosset. 1996. A blind study of the polymerase
chain reaction for the detection of Mycobacterium tuberculosis DNA. Azay Mycobacteria Study Group.
Tuber Lung Dis. 77:358-62.
Grosset, J. 1996. [Bacteriological diagnosis of tuberculosis]. Rev Prat. 46:1337-43.
Grosset J.. 1996. L'approche expérimentale de la chimiothérapie de la tuberculose.
Méd. Mal. Infect.; 26 : 922-925.
Grosset J. Résurgence de maladies anciennes : la tuberculose.
Rev. Epid. Santé Publique 1996 ; 44 (suppl. 2) : S11.
Grosset, J. 1996. Current problems with tuberculosis treatment. Res Microbiol. 147:10-6.
Ji, B., P. Jamet, E. G. Perani, S. Sow, C. Lienhardt, C. Petinon, and J. H. Grosset. 1996. Bactericidal
activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against
Mycobacterium leprae in patients. Antimicrob Agents Chemother. 40:2137-41.
Ji, B., L. Levy, and J. H. Grosset. 1996. Chemotherapy of leprosy: progress since the Orlando
Congress, and prospects for the future. Int J Lepr Other Mycobact Dis. 64:S80-8; discussion S88-90.
Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1996. How effective is KRM-1648 in treatment of
disseminated Mycobacterium avium complex infections in beige mice? Antimicrob Agents Chemother.
40:437-42.
Ji, B., E. G. Perani, C. Petinom, and J. H. Grosset. 1996. Bactericidal activities of combinations of
new drugs against Mycobacterium leprae in nude mice. Antimicrob Agents Chemother. 40:393-9.
Lemaitre, N., W. Sougakoff, D. Coetmeur, J. Vaucel, V. Jarlier, and J. Grosset. 1996. Nosocomial
transmission of tuberculosis among mentally-handicapped patients in a long-term care facility. Tuber
Lung Dis. 77:531-6.
Lemaitre, N., W. Sougakoff, C. Truffot, J. Grosset, and V. Jarlier. 1996. [Analysis of restriction
fragment length polymorphism (RFLP) of Mycobacterium tuberculosis strains isolated from patients
with several episodes of tuberculosis]. Pathol Biol (Paris). 44:452-5.
7
Traore, I., B. Ji, C. Lienhardt, P. Bobin, and J. Grosset. 1996. Determination of the minimal effective
dosages of ofloxacin and sparfloxacin against M. leprae in the mouse foot pad system. Int J Lepr
Other Mycobact Dis. 64:142-5.
Year 1995
Baril, L., E. Caumes, C. Truffot-Pernot, F. Bricaire, J. Grosset, and M. Gentilini. 1995. Tuberculosis
caused by Mycobacterium africanum associated with involvement of the upper and lower respiratory
tract, skin, and mucosa. Clin Infect Dis. 21:653-5.
Chaulet, P., F. Boulahbal, and J. Grosset. 1995. Surveillance of drug resistance for tuberculosis
control: why and how? Tuber Lung Dis. 76:487-92.
Cohen, Y., C. Perronne, T. Lazard, C. Truffot-Pernot, J. Grosset, J. L. Vilde, and J. J. Pocidalo. 1995.
Use of normal C57BL/6 mice with established Mycobacterium avium infections as an alternative model
for evaluation of antibiotic activity. Antimicrob Agents Chemother. 39:735-8.
Doucet-Populaire, F., C. Truffot-Pernot, J. Grosset, and V. Jarlier. 1995. Acquired resistance in
Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment
with clarithromycin. J Antimicrob Chemother. 36:129-36.
Enarson, D. A., J. Grosset, A. Mwinga, E. S. Hershfield, R. O'Brien, S. Cole, and L. Reichman. 1995.
The challenge of tuberculosis: statements on global control and prevention. Lancet. 346:809-19.
Grosset, J., and Y. Mouton. 1995. Is PCR a useful tool for the diagnosis of tuberculosis in 1995?
Tuber Lung Dis. 76:183-4.
Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1995. In vitro and in vivo activities of levofloxacin
against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 39:1341-4.
Lounis, N., B. Ji, C. Truffot-Pernot, and J. Grosset. 1995. Selection of clarithromycin-resistant
Mycobacterium avium complex during combined therapy using the beige mouse model. Antimicrob
Agents Chemother. 39:608-12.
Struillou, L., Y. Cohen, N. Lounis, G. Bertrand, J. Grosset, J. L. Vilde, J. J. Pocidalo, and C. Perronne.
1995. Activities of roxithromycin against Mycobacterium avium infections in human macrophages and
C57BL/6 mice. Antimicrob Agents Chemother. 39:878-81.
Truffot-Pernot, C., N. Lounis, J. H. Grosset, and B. Ji. 1995. Clarithromycin is inactive against
Mycobacterium tuberculosis. Antimicrob Agents Chemother. 39:2827-8.
Year 1994
Cambau, E., W. Sougakoff, M. Besson, C. Truffot-Pernot, J. Grosset, and V. Jarlier. 1994. Selection
of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with
ofloxacin. J Infect Dis. 170:1351.
Chapuis, L., B. Ji, C. Truffot-Pernot, R. J. O'Brien, M. C. Raviglione, and J. H. Grosset. 1994.
Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir
Crit Care Med. 150:1355-62.
Grosset, J. H. 1994. Assessment of new therapies for infection due to the Mycobacterium avium
complex: appropriate use of in vitro and in vivo testing. Clin Infect Dis. 18:S233-6.
Grosset, J. H. 1994. Progress in the chemotherapy of leprosy. Int J Lepr Other Mycobact Dis. 62:26877.
Heym, B., N. Honore, C. Truffot-Pernot, A. Banerjee, C. Schurra, W. R. Jacobs, Jr., J. D. van Embden,
8
J. H. Grosset, and S. T. Cole. 1994. Implications of multidrug resistance for the future of short-course
chemotherapy of tuberculosis: a molecular study. Lancet. 344:293-8.
Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1994. Effectiveness of various antimicrobial
agents against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents
Chemother. 38:2521-9.
Ji, B., E. G. Perani, C. Petinom, L. N'Deli, and J. H. Grosset. 1994. Clinical trial of ofloxacin alone and
in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrob Agents
Chemother. 38:662-7.
Lazard, T., C. Perronne, C. Truffot-Pernot, J. Grosset, J. L. Vilde, and J. J. Pocidalo. 1994.
Chloroquine does not enhance the activity of clarithromycin against multiplication of Mycobacterium
avium within human macrophages. Tuber Lung Dis. 75:283-5.
Vareldzis, B. P., J. Grosset, I. de Kantor, J. Crofton, A. Laszlo, M. Felten, M. C. Raviglione, and A.
Kochi. 1994. Drug-resistant tuberculosis: laboratory issues. World Health Organization
recommendations. Tuber Lung Dis. 75:1-7.
Xiong, J. H., B. Ji, E. G. Perani, C. Petinon, and J. H. Grosset. 1994. Further study of the
effectiveness of single doses of clarithromycin and minocycline against Mycobacterium leprae in mice.
Int J Lepr Other Mycobact Dis. 62:37-42.
Year 1993
Dautzenberg, B., T. Saint Marc, M. C. Meyohas, M. Eliaszewitch, F. Haniez, A. M. Rogues, S. De Wit,
L. Cotte, J. P. Chauvin, and J. Grosset. 1993. Clarithromycin and other antimicrobial agents in the
treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency
syndrome. Arch Intern Med. 153:368-72.
Glaziou, P., J. L. Cartel, J. P. Moulia-Pelat, L. N. Ngoc, S. Chanteau, R. Plichart, and J. H. Grosset.
1993. Tuberculosis in leprosy patients detected between 1902 and 1991 in French Polynesia. Int J
Lepr Other Mycobact Dis. 61:199-204.
Hejblum, G., V. Jarlier, J. Grosset, and A. Aurengo. 1993. Automated interpretation of disk diffusion
antibiotic susceptibility tests with the radial profile analysis algorithm. J Clin Microbiol. 31:2396-401.
Honore, N., E. Perrani, A. Telenti, J. Grosset, and S. T. Cole. 1993. A simple and rapid technique for
the detection of rifampin resistance in Mycobacterium leprae. Int J Lepr Other Mycobact Dis. 61:600-4.
Ji, B., C. Truffot-Pernot, C. Lacroix, M. C. Raviglione, R. J. O'Brien, P. Olliaro, G. Roscigno, and J.
Grosset. 1993. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of
tuberculosis in mice. Am Rev Respir Dis. 148:1541-6.
Ji, B., P. Jamet, E. G. Perani, P. Bobin, and J. H. Grosset. 1993. Powerful bactericidal activities of
clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J Infect Dis.
168:188-90.
Lalande, V., C. Truffot-Pernot, A. Paccaly-Moulin, J. Grosset, and B. Ji. 1993. Powerful bactericidal
activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents
Chemother. 37:407-13.
Lazard, T., C. Perronne, J. Grosset, J. L. Vilde, and J. J. Pocidalo. 1993. Clarithromycin, minocycline,
and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium.
Antimicrob Agents Chemother. 37:1690-2.
Lazard, T., C. Perronne, Y. Cohen, J. Grosset, J. L. Vilde, and J. J. Pocidalo. 1993. Efficacy of
granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against
Mycobacterium avium complex infection in C57BL/6 mice. Antimicrob Agents Chemother. 37:692-5.
9
Year 1992
Cartel, J. L., J. P. Boutin, A. Spiegel, P. Glaziou, R. Plichart, R. Cardines, and J. H. Grosset. 1992.
Leprosy in French Polynesia. Epidemiological trends between 1946 and 1987. Lepr Rev. 63:211-22.
Cartel, J. L., A. Spiegel, L. Nguyen Ngoc, J. P. Moulia-Pelat, P. M. Martin, and J. H. Grosset. 1992.
Leprosy in French Polynesia. The possible impact of multidrug therapy on epidemiological trends. Lepr
Rev. 63:223-30.
Cartel, J. L., S. Chanteau, J. P. Moulia-Pelat, R. Plichart, P. Glaziou, J. P. Boutin, J. F. Roux, and J. H.
Grosset. 1992. Chemoprophylaxis of leprosy with a single dose of 25 mg per kg rifampin in the
southern Marquesas; results after four years. Int J Lepr Other Mycobact Dis. 60:416-20.
Cohen, Y., C. Perronne, C. Truffot-Pernot, J. Grosset, J. L. Vilde, and J. J. Pocidalo. 1992. Activities
of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium
avium complex in human macrophages. Antimicrob Agents Chemother. 36:2104-7.
Couderc, L. J., B. Epardeau, M. C. Dazza, J. P. Clauvel, B. Autran, J. Grosset, and I. Caubarrere.
1992. Disseminated Mycobacterium avium intracellulare infection without predisposing conditions.
Lancet. 340:731.
Grosset, J., C. Truffot-Pernot, C. Lacroix, and B. Ji. 1992. Antagonism between isoniazid and the
combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents
Chemother. 36:548-51.
Grosset, J. H. 1992. Treatment of tuberculosis in HIV infection. Tuber Lung Dis. 73:378-83.
119
Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1992. Selection of resistant mutants of
Mycobacterium avium in beige mice by clarithromycin monotherapy. Antimicrob Agents Chemother.
36:2839-40.
Ji, B., E. G. Perani, C. Petinon, and J. H. Grosset. 1992. Bactericidal activities of single or multiple
doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice. Int J
Lepr Other Mycobact Dis. 60:556-61.
Perronne, C., Y. Cohen, C. Truffot-Pernot, J. Grosset, J. L. Vilde, and J. J. Pocidalo. 1992.
Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated
Mycobacterium avium complex infection of normal C57BL/6 mice. Antimicrob Agents Chemother.
36:2408-12.
Pretet, S., A. Lebeaut, R. Parrot, C. Truffot, J. Grosset, and A. T. Dinh-Xuan. 1992. Combined
chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis.
G.E.T.I.M. (Group for the Study and Treatment of Resistant Mycobacterial Infection). Eur Respir J.
5:680-4.
Rouby, J. J., E. Martin De Lassale, P. Poete, M. H. Nicolas, L. Bodin, V. Jarlier, Y. Le Charpentier, J.
Grosset, and P. Viars. 1992. Nosocomial bronchopneumonia in the critically ill. Histologic and
bacteriologic aspects. Am Rev Respir Dis. 146:1059-66.
Schwoebel, V., B. Hubert, and J. Grosset. 1992. Impact of BCG on tuberculous meningitis in France
in 1990. Lancet. 340:611.
Year 1991
Constant-Desportes, M., C. C. Guelpa-Lauras, J. C. Carolina, A. Leoture, J. H. Grosset, and H.
Sansarricq. 1991. A case of relapse with drug-susceptible M. leprae after multidrug therapy. Int J Lepr
Other Mycobact Dis. 59:242-7.
10
Dautzenberg, B., C. Truffot, S. Legris, M. C. Meyohas, H. C. Berlie, A. Mercat, S. Chevret, and J.
Grosset. 1991. Activity of clarithromycin against Mycobacterium avium infection in patients with the
acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis. 144:564-9.
Dautzenberg, B., C. Truffot, A. Mignon, W. Rozenbaum, C. Katlama, C. Perronne, R. Parrot, and J.
Grosset. 1991. Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of
AIDS patients with infections due to opportunist mycobacteria. Groupe d'Etude et de Traitement des
Infections a Mycobacteries Resistantes. Tubercle. 72:168-75.
Ji, B., C. Truffot-Pernot, and J. Grosset. 1991. In vitro and in vivo activities of sparfloxacin (AT-4140)
against Mycobacterium tuberculosis. Tubercle. 72:181-6.
Ji, B., E. G. Perani, and J. H. Grosset. 1991. Effectiveness of clarithromycin and minocycline alone
and in combination against experimental Mycobacterium leprae infection in mice. Antimicrob Agents
Chemother. 35:579-81.
Ji, B., and J. Grosset. 1991. Ofloxacin for the treatment of leprosy. Acta Leprol. 7:321-6.
Perronne, C., A. Gikas, C. Truffot-Pernot, J. Grosset, J. L. Vilde, and J. J. Pocidalo. 1991. Activities of
sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against
multiplication of Mycobacterium avium complex within human macrophages. Antimicrob Agents
Chemother. 35:1356-9
Truffot-Pernot, C., B. Ji, and J. Grosset. 1991. Effect of pH on the in vitro potency of clarithromycin
against Mycobacterium avium complex. Antimicrob Agents Chemother. 35:1677-8.
Truffot-Pernot, C., B. Ji, and J. Grosset. 1991. Activities of pefloxacin and ofloxacin against
mycobacteria: in vitro and mouse experiments. Tubercle. 72:57-64.
Year 1990
Abel, L., V. V. Cua, J. Oberti, V. D. Lap, L. K. Due, J. Grosset, and P. H. Lagrange. 1990. Leprosy
and BCG in southern Vietnam. Lancet. 335:1536.
Cartel, J. L., S. Chanteau, J. P. Boutin, R. Plichart, P. Richez, J. F. Roux, and J. H. Grosset. 1990.
Assessment of anti-phenolic glycolipid-I IgM levels using an ELISA for detection of M. leprae infection
in populations of the South Pacific Islands. Int J Lepr Other Mycobact Dis. 58:512-7.
Chanteau, S., J. L. Cartel, E. Perani, L. N'Deli, J. Roux, and J. H. Grosset. 1990. Relationships
between PGL-1 antigen in serum, tissue and viability of Mycobacterium leprae as determined by
mouse footpad assay in multibacillary patients during short-term clinical trial. Lepr Rev. 61:330-40
Grosset, J. 1990. [Norfloxacin: a broad-spectrum quinolone for superficial eye infections]. Pathol Biol
(Paris). 38:735-41.
Grosset, J. H., B. H. Ji, C. C. Guelpa-Lauras, E. G. Perani, and L. N. N'Deli. 1990. Clinical trial of
pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis.
58:281-95.
Grosset, J. 1990. Present and new drug regimens in chemotherapy and chemoprophylaxis of
tuberculosis. Bull Int Union Tuberc Lung Dis. 65:86-91.
Grosset, J. 1990. [Bacteriologic basis for the treatment of tuberculosis]. Rev Prat. 40:715-8.
Grosset, J., H. Boisvert, C. Truffot-Pernot, and C. Rica. 1990. Organization of laboratory services
in low prevalence countries, our personal view. Bull Int Union Tuberc Lung Dis. 65:60-3.
Grosset, J. 1990. New experimental regimens for preventive therapy of tuberculosis. Bull Int Union
Tuberc Lung Dis. 66:15-6.
11
Ji, B., and J. H. Grosset. 1990. Recent advances in the chemotherapy of leprosy. Lepr Rev. 61:31329.
N'Deli, L., C. C. Guelpa-Lauras, E. G. Perani, and J. H. Grosset. 1990. Effectiveness of pefloxacin in
the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis. 58:12-8.
Perronne, C., A. Gikas, C. Truffot-Pernot, J. Grosset, J. J. Pocidalo, and J. L. Vilde. 1990. Activities of
clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within
human macrophages. Antimicrob Agents Chemother. 34:1508-11.
Schwoebel, V., B. Hubert, and J. Grosset. 1994. Tuberculous meningitis in France in 1990:
characteristics and impact of BCG vaccination. Tuber Lung Dis. 75:44-8.
Year 1989
.
Cartel, J. L., S. Chanteau, J. P. Boutin, R. Taylor, R. Plichart, J. Roux, P. Celerier, and J. H. Grosset.
1989. Implementation of chemoprophylaxis of leprosy in the Southern Marquesas with a single dose of
25 mg per kg rifampin. Int J Lepr Other Mycobact Dis. 57:810-6.
Grosset, J. H., J. Baohong, and S. K. Noordeen. 1989. Comments on an editorial by B. R. Chatterjee
"On Multi-Drug Combinations in the Treatment of Leprosy". Indian J Lepr. 61:323-7.
Grosset, J. H., C. C. Guelpa-Lauras, P. Bobin, G. Brucker, J. L. Cartel, M. Constant-Desportes, B.
Flageul, M. Frederic, J. C. Guillaume, and J. Millan. 1989. Study of 39 documented relapses of
multibacillary leprosy after treatment with rifampin. Int J Lepr Other Mycobact Dis. 57:607-14.
Grosset, J. H. 1989. Present status of chemotherapy for tuberculosis. Rev Infect Dis. 11:S347-52.
Grosset, J. H., and B. H. Ji. 1989. Controlled clinical trial for evaluation of antimicrobial drug activity
against M. leprae. Int J Lepr Other Mycobact Dis. 57:529-31.
Jarlier, V., M. H. Nicolas, A. Philippon, A. M. Giroir, and J. Grosset. 1989. In-vitro activity of FCE
22101 and other beta-lactam antibiotics against Enterobacteriaceae resistant to third generation
cephalosporins. J Antimicrob Chemother. 24:165-72.
Lecoeur, H. F., P. H. Lagrange, C. Truffot-Pernot, M. Gheorghiu, and J. Grosset. 1989. Relapses
after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible
strains of mice. Clin Exp Immunol. 76:458-62.
Lecoeur, H. F., C. Truffot-Pernot, and J. H. Grosset. 1989. Experimental short-course preventive
therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis. 140:1189-93.
Rouby, J. J., M. D. Rossignon, M. H. Nicolas, E. Martin de Lassale, S. Cristin, J. Grosset, and P.
Viars. 1989. A prospective study of protected bronchoalveolar lavage in the diagnosis of nosocomial
pneumonia. Anesthesiology. 71:679-85.
Truffot-Pernot, C., H. F. Lecoeur, L. Maury, B. Dautzenberg, and J. Grosset. 1989. Results of blood
cultures for detection of mycobacteria in AIDS patients. Tubercle. 70:187-91
Year 1988
Cartel, J. L., J. P. Boutin, R. Plichart, J. Roux, and J. H. Grosset. 1988. Leprosy in the French
Polynesian archipelagoes from 1967 to 1987. Bull Soc Pathol Exot Filiales. 81:819-26.
Dautzenberg, B., and J. Grosset. 1988. Tuberculosis and pregnancy. Rev Mal Respir. 5:279-83.
Grosset, J. H., C. C. Guelpa-Lauras, E. G. Perani, and C. Beoletto. 1988. Activity of ofloxacin against
Mycobacterium leprae in the mouse. Int J Lepr Other Mycobact Dis. 56:259-64.
12
Grosset, J. H., C. Truffot-Pernot, and H. Lecoeur. 1988. [New and future drugs in pulmonary
tuberculosis]. Prax Klin Pneumol. 42:206-10.
Lepetit, C., A. Thebaud-Mony, and J. Grosset. 1988. [Tuberculosis in the Department of Seine-Saint
Denis. I. Cases under treatment in 1984]. Rev Mal Respir. 5:129-36.
Mitchison, D. A., G. A. Ellard, and J. Grosset. 1988. New antibacterial drugs for the treatment of
mycobacterial disease in man. Br Med Bull. 44:757-74
Parrot, R. G., and J. H. Grosset. 1988. Post-surgical outcome of 57 patients with Mycobacterium
xenopi pulmonary infection. Tubercle. 69:47-55.
Truffot-Pernot, C., A. M. Giroir, L. Maury, and J. Grosset. 1988. [Study of the minimal inhibitory
concentration of rifabutine (Ansamycin LM 427) for Mycobacterium tuberculosis, Mycobacterium
xenopi and Mycobacterium avium-intracellulare]. Rev Mal Respir. 5:401-6.
Year 1987
Cartel, J. L., Y. Naudillon, J. C. Remy, and J. H. Grosset. 1987. Contribution of relapses to total
infection sources of leprosy in Guadeloupe. Lepr Rev. 58:339-48.
Grosset, J. H. 1987. Pharmacokinetics in drug screening. Int. J. Lepr. Other Mycobact. Dis. 55:852-6.
McDermott-Lancaster, R. D., T. Ito, K. Kohsaka, C. C. Guelpa-Lauras, and J. H. Grosset. 1987.
Multiplication of Mycobacterium leprae in the nude mouse, and some applications of nude mice to
experimental leprosy. Int J Lepr Other Mycobact Dis. 55:889-95.
Grosset, J., C. C. Guelpa-Lauras, J. Millan, M. Bodian, and E. Perani. 1987. [Resistance of
Mycobacterium leprae to dapsone and rifampicin: apropos of a survey carried out in the Cape Verde
region (Senegal)]. Med Trop (Mars). 47:171-5.
Grosset, J., V. Jarlier, and H. Lecoeur. 1987. [BCG vaccination in France]. Rev Mal Respir. 4:69-74.
Grosset, J., and H. Lecoeur. 1987. [Present status of vaccination against leprosy]. Acta Leprol. 5:231239.
Grosset, J. H., J. B; Ji, and T. Ito. 1987. The first joint THELEP-Sasakawa Memorial Health
Foundation workshop on experimental chemotherapy of leprosy. Int J Lepr Other Mycobact Dis.
55:807-13.
Grosset, J. H., and C. C. Guelpa-Lauras. 1987. Activity of rifampin in infections of normal mice with
Mycobacterium leprae. Int J Lepr Other Mycobact Dis. 55:847-51.
Guelpa-Lauras, C. C., E. G. Perani, A. M. Giroir, and J. H. Grosset. 1987. Activities of pefloxacin and
ciprofloxacin against Mycobacterium leprae in the mouse. Int J Lepr Other Mycobact Dis. 55:70-7.
Mouquet, C., J. Fusciardi, M. P. Stoupak, G. Vallancien, V. Jarlier, C. Chatelain, J. Grosset, and P.
Viars. 1987. [Transurethral surgery and persistent urinary infection: effect of a single preoperative
dose of cefuroxime]. Pathol Biol (Paris). 35:1243-7.
Year 1986
Cartel, J. C., J. J. Gallais, Y. Naudillon, J. Millan, and J. H. Grosset. 1986. [5-year assessment of daily
multi-drug therapy of leprosy in Guadeloupe since 1980]. Acta Leprol. 4:415-25.
Cartel, J. L., J. J. Gallais, Y. Naudillon, J. G. Remy, and J. H. Grosset. 1986. [Epidemiology of leprosy
in Guadeloupe from 1970 to 1984]. Acta Leprol. 4:161-73.
Choudat, D., P. Horreard, S. Pretet, J. Grosset, and L. Toty. 1986. Superinfection by Aspergillus
fumigatus of a pulmonary lesion caused by Mycobacterium xenopi. Tubercle. 67:71-4.
13
Constant-Desportes-Relouzat, M., J. Grosset, C. C. Guelpalauras, B. Salvini, and D. Cales-Quist.
1986. Dynamics of establishing resistance of M. leprae to dapsone and rifampicin in Martinique. Acta
Leprol. 4:293-300.
Dautzenberg, B., C. Gallinari, G. Aeberhardt, A. Levy, J. Bernheim, J. Grosset, and C. Sors. 1986.
Routine use of 6-month antitubercular treatment in 300 patients. Presse Med. 15:2151-2, 2157-8.
Grosset, J. H. 1986. Recent developments in the field of multidrug therapy and future research in
chemotherapy of leprosy. Lepr Rev. 57:223-34.
Grosset, J., and H. Lecoeur. 1986. [Vaccination against leprosy]. Acta Leprol. 4:289-91.
Jarlier, V., C. J. Soussy, M. Chanal, D. Sirot, J. Le Van Thoi, R. Bismuth, J. Grosset, J. Duval, and R.
Cluzel. 1986. [In vitro effect of piperacillin on aerobic bacteria. Variations according to the phenotypes
of resistance to beta-lactam antibiotics]. Presse Med. 15:2272-8.
Millan, J., M. Bodian, J. C. Naudin, B. Diouf, P. Boucher, B. Ndoye, and J. Grosset. 1986. [A trial of
polychemotherapy of leprosy in the Dakar region. Initial observations on the acceptability of the
protocols used]. Acta Leprol. 4:19-35.
Millan, J., G. Roux, S. Loko, J. C. Naudin, P. Boucher, M. Bodian, M. Camara, T. Moreira-Diop, and J.
Grosset. 1986. [Multi-drug therapy trials for leprosy in Senegal: first observations relative to liver
tolerance of multibacillary patients. Therapeutic consequences]. Acta Leprol. 4:427-44.
Sebille, A., M. O. Crepon, C. C. Guelpa, and J. Grosset. 1986. Electrophysiologic demonstration of
the activity of rifampicin on nerve disease developing in mice inoculated with Hansen's bacilli in the
footpad. Acta Leprol. 4:215.
Soga, G., L. Blanc, C. Alfa, J. Grosset, and X. Surmont. 1986. [Combined treatments consisting of
rifampicin in periodic doses: the experience in Niger]. Acta Leprol. 4:397-407.
Year 1985
Cartel, J. L., Y. Naudillon, J. C. Artus, and J. H. Grosset. 1985. [Epidemiology of leprosy in
Guadalupe between 1970 and 1983]. Bol Oficina Sanit Panam. 98:535-47
Cartel, J. L., J. J. Gallais, and J. H. Grosset. 1985. [Acceptability, compliance and tolerance of daily
polychemotherapy by leprosy patients in Guadeloupe]. Acta Leprol. 3:339-55
Cartel, J. L., Y. Naudillon, J. C. Artus, and J. H. Grosset. 1985. Hepatotoxicity of the daily combination
of 5 mg/kg prothionamide + 10 mg/kg rifampin. Int J Lepr Other Mycobact Dis. 53:15-8.
Grosset, J., L. Levy, R. J. Rees, and C. C. Shepard. 1985. Drug sensitivity testing of M. leprae. Int J
Lepr Other Mycobact Dis. 53:118-21.
Grosset, J., C. Truffot-Pernot, S. Poggi, H. Lecoeur, and C. Chastang. 1985. Prevention of resistance
to rifampicin by pyrazinamide in experimental tuberculosis in the mouse. Rev Mal Respir. 2:205-8.
Grosset, J. 1985. Bacteriological bases of short-course chemotherapy. Rev Ig Bacteriol Virusol
Parazitol Epidemiol Pneumoftiziol Pneumoftiziol. 34:103-7.
Grosset, J. 1985. Mechanisms of action of antituberculosis drugs in standard and short-course
chemotherapy regimens. Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol.
34:108-15.
Nebout, M., and J. Grosset. 1985. [Present-day difficulties in the campaign against leprosy and
proposals for its resumption in French-speaking Africa]. Acta Leprol. 3:233-7.
14
Sebille, A., M. O. Crepon, C. C. Guelpa, and J. Grosset. 1985. Evidence for the activity of rifampin on
the neuropathy of foot pad-inoculated mice with Mycobacterium leprae. Int J Lepr Other Mycobact Dis.
53:481-3.
Sors, C., E. Bouvet, J. Grosset, S. Perdrizet, and S. Pretet. 1985. Aspects of tuberculosis in France.
Rev Infirm. 35:29-34.
Year 1984
Jarlier, V., R. Bismuth, M. H. Nicolas, J. Nguyen, C. Truffot, and J. Grosset. 1984. Survey of the
phenotypes of susceptibility to beta-lactams in Enterobacteriaceae at the Pitie-Salpetriere Hospital. J
Antimicrob Chemother. 14:59-65.
.Grosset, J., and C. Sors. 1984. [Mycobacterioses]. Presse Med. 13:215-8.
Jarlier, V., C. Truffot-Pernot, and J. Grosset. 1984. Potential value of the amoxicillin-clavulanic acid
combination in general medicine, gynecology-obstetrics and pediatrics departments. Pathol Biol
(Paris). 32:492-5.
Dautzenberg, B., J. Grosset, J. Fechner, J. Lucciani, P. Debre, S. Herson, C. Truffot, and C. Sors.
1984. The management of thirty immunocompromised patients with tuberculosis. Am Rev Respir Dis.
129:494-6.
Giroulle, H., L. Bernabeu, H. Boisvert, C. Truffot, and J. Grosset. 1984. [Pulmonary mycobacteriosis
due to a non-chromogenic, slow-growing, unclassified mycobacterium]. Rev Mal Respir. 1:161-4.
Grosset, J. 1984. [Advances in the chemotherapy of leprosy]. Med Trop (Mars). 44:17-22.
Guelpa-Lauras, C. C., J. H. Grosset, M. Constant-Desportes, and G. Brucker. 1984. Nine cases of
rifampin-resistant leprosy. Int J Lepr Other Mycobact Dis. 52:101-2.
Year 1983
Grosset, J., C. Truffot-Pernot, H. Lecoeur, and C. C. Guelpa-Lauras. 1983. [Activity of rifampicin
administered daily and intermittently on experimental tuberculosis in mice]. Pathol Biol (Paris). 31:44650.
Grosset, J., C. Truffot-Pernot, R. Bismuth, and H. Lecoeur. 1983. [Recent data on the chemotherapy
of experimental tuberculosis in the mouse]. Bull Int Union Tuberc. 58:90-6.
Bismuth, R., V. Jarlier, and J. Grosset. 1983. [In vitro synergy between sulfamethoxazole and
trimethoprim on strains of Staphylococcus aureus sensitive and resistant to methicillin]. Pathol Biol
(Paris). 31:429-33.
Cartel, J. L., J. Millan, C. C. Guelpa-Lauras, and J. H. Grosset. 1983. Hepatitis in leprosy patients
treated by a daily combination of dapsone, rifampin, and a thioamide. Int J Lepr Other Mycobact Dis.
51:461-5.
Cooreman, J., G. Burghard, and J. Grosset. 1983. Resistance of the Koch bacillus to antibacillary
agents in the Department of the Lower Rhine. Rev Fr Mal Respir. 11:699-704.
Jarlier, V., R. Bismuth, and J. Grosset. 1983. Cefotaxime, moxalactam and ceftriaxone: comparison of
in vitro activity against hospital strains of Enterobacteriaceae belonging to the 4 principal phenotypes
of sensitivity to beta-lactams. Pathol Biol (Paris). 31:336-42.
15
Truffot-Pernot, C., J. Grosset, R. Bismuth, and H. Lecoeur. 1983. [Activity of intermittently
administered rifampicin and cyclopentyl rifamycin (or DL473) on experimental tuberculosis in the
mouse]. Rev Fr Mal Respir. 11:875-82.
Grosset, J., and S. Leventis. 1983. Adverse effects of rifampin. Rev Infect Dis. 5:S440-50.
Parrot, R., C. Boval, J. Grosset, and J. P. Gaillard. 1983. [Adjusting or not adjusting isoniazid
dosage?]. Rev Fr Mal Respir. 11:705-12.
Year 1982
Grosset, J., and C. Truffot-Pernot. 1982. [Laboratories: their role in the diagnosis and treatment of
tuberculosis]. Bull Int Union Tuberc. 57:234-41.
Grosset, J., C. Truffot, J. Fermanian, and H. Lecoeur. 1982. [Sterilizing activity of the main drugs on
the mouse experimental tuberculosis (author's transl)]. Pathol Biol (Paris). 30:444-8.
Guelpa-Lauras, C. C., J. Grosset, C. Truffot-Pernot, and A. M. Giroir. 1982. Comparative bactericidal
action of rifampicin alone on M. tuberculosis and M. leprae. Acta Leprol:69-75.
Grosset, J., and C. Truffot-Pernot. 1982. Biology of the tubercle bacillus. Rev Med Suisse Romande.
102:257-63.
Guelpa-Lauras, C. C., M. Constant-Desportes, J. Millan, and J. Grosset. 1982. Resistance of
Mycobacterium leprae to sulfones (DDS) and rifampicin in recurring lepromatous leprosy in Martinique
and Guadeloupe since February 1980. Acta Leprol:77-80.
Grosset, J., R. Bismuth, and J. Nguyen. 1982. [Pharmacokinetic basis for antibiotic therapy in
broncho-pulmonary bacterial infections (author's transl)]. Rev Fr Mal Respir. 10:195-203.
.Grosset, J., C. C. Guelpa-Lauras, and H. Lecoeur. 1982. [Current data on the bacteriology of
leprosy]. Acta Leprol:35-45.
Sors, C., B. Dautzenberg, and J. Grosset. 1982. [Duration of the treatment of tuberculosis in 1981].
Nouv Presse Med. 11:831.
Grosset, J., C. Truffot, and C. Boval. 1982. The role of low dosage prothionamide with and without
4,4'-diamino diphenyl sulphone for use with isoniazid in the treatment of experimental mouse
tuberculosis. Tubercle. 63:37-43.
Nguyen, J., B. Dautzenberg, J. Grosset, and C. Sors. 1982. [Results of antibiotic sensitivity and
"Streptococcus pneumoniae" serotype tests in the Pitie-Salpetriere hospital, France, 1979-1980
(author's transl)]. Rev Fr Mal Respir. 10:115-20.
Year 1981
Grosset, J. 1981. Studies in short-course chemotherapy for tuberculosis. Basis for short-course
chemotherapy. Chest. 80:719-20.
Year 1980
Grosset, J. 1980. Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin Chest Med.
1:231-41.
Grosset, J. 1980. The efficacy of short-course chemotherapy for tuberculosis. Bull Pan Am Health
Organ. 14:139-49.
16
Year 1979
Dautzenberg, B., J. Nguyen, J. Grosset, and C. Sors. 1979. A comparative study of three procedures
used for studying bronchopulmonary bacterial flora (author's transl). Ann Med Interne (Paris).
130:415-8.
Grosset, J. 1979. [The bacteriological principles of tuberculosis treatments]. Rev Prat. 29:2645-50.
Grosset J., L. Meyer, C. Truffot, C. Boval.1979. Mycobacterium xenopi: caracteres bacteriologiques et
sensibilité aux antibiotiques. Rev. Fr. Mal. Resp. 7. 498-500.
Parrot R., JM Braun, JP Gaillard, Ch Sors and J. Grosset. 1979. les mycobactérioses à
Mycobacterium xenopi. A propos de 50 cas. I. Eléments du diagnostic. Rev. Fr. Mal. Resp. 7. 501503
.
Year 1978
Chaix Y., R. Thibier, V. Jarlier, J. Labas, and J. Grosset. Recensement de la tuberculose dans le
département des Yvelines en 1973. Rev. Fr. Mal. Resp. 6. 239-241.
Gaillard JP., R. Parrot, and J. Grosset. Une nouvelle hypothèse pour expliquer l'absence de
contagiosité des tuberculeux bacillifères sous traitement. Rev. Fr. Mal. Resp. 6. 316-318.
Grosset J. 1978. La place de l'antibiogramme dans les nouveaux cas de tuberculose. Rev. Fr. Mal.
Resp. 6. 244-8.
Grosset, J. 1978. The sterilizing value of rifampicin and pyrazinamide in experimental short-course
chemotherapy. Bull Int Union Tuberc. 53:5-12.
Grosset, J. 1978. [Short term chemotherapy of tuberculosis. Current experimental findings in short
term chemotherapy]. Bull Int Union Tuberc. 53:281-3.
Grosset J., F. Grumbach and N. Rist. 1978. Le role de la rifampicine dans la phase ultime du
traitement de la tuberculose murine experimentale. Rev. Fr. Mal. Resp. 6. 515- 520.
Pretet, S., J. Grosset, and S. Perdrizet. 1978. [Short term chemotherapy of tuberculosis. Evaluation of
an 18-week-long treatment including pyrazinamide (preliminary results)]. Bull Int Union Tuberc.
53:260-1.
Year 1977
Year 1976
Grosset, J., P. Glaser, A. Baud, and R. Bismuth. 1976. [Bacterial flora in pneumopathies and its
significance in surgical resuscitation]. Lille Med. 21:97-9.
Year 1975
Larbaoui D., P; Chaulet. and J. Grosset. 1975. Le traitement de relais de la tuberculose pulmonaire
par administration intermittente de rifampicine et d'éthambutol.Rev. Fr. Mal. Resp. 3. 44-48.
Grumbach F, and J. Grosset. 1975. Le Pyrazinamide dans le traitement de courte durée de la
tuberculose murine. Rev. Fr. Mal. Resp. 3. 5-18.
Year 1974
17
Bismuth R., J. Grosset, G. Pacaud and Ch Truffot.1974. Etude de la sensibilité des entérobactéries à
la minocycline. Gazette Médicale de France. Monographie thérapeutique: problèmes actuels en
antibiothérapie. p. 3-8.
Grosset J. Hiérarchie des médicaments antibacillaires. Données biologiques. Rapport au XVIIe
Congres National de la tuberculose et des maladies respiratoires. Masson et Cie, 1974, p. 3-25.
Grosset J. S. Sangaré, N. Rist and L. Meyer.1974. Caractères culturaux et biochimiques des bacilles
tuberculeux isolés chez 230 tuberculeux pulmonaires au Mali. Bull. Int. Union Tuberc. 49. 190- 200.
Year 1973
Pacaud, G., J. Grosset, and R. Bismuth. 1973. La sensibilité bactérienne à l'association
sulfamethoxazole-trimethoprime. Med. et Mal. Inf. 3: 293-296.
Vayssairat, M., R. Moulias, P. Rameix, J. Grosset, G. Chomette, and J. Loeper. 1973. [Two new
cases of pulmonary mycobacteriosis due to Mycobacterium xenopi]. Ann Med Interne (Paris).
124:309-12.
Year 1972
Canetti, G., M. Le Lirzin, P. Gay, R. Thibier, B. Kreis, and J. Grosset. 1972. [Primary resistance in
adult pulmonary tuberculosis in France. 3d report of the study center on Primary Resistance: 19661970]. Rev Tuberc Pneumol (Paris). 36:337-56
Grosset J., R. Bismuth and C Sors. 1972.Taux seriques d'ethambutol apres administration orale et
parenterale. Gazette Med de France 79: 7309-7311.
Sors C and J. Grosset. 1972. Incidence des donnees biologiques sur la place de l'ethambutol en
therapeutique antituberculeuse. Gazette Med de France 79: 7360-7363
Year 1971
Grosset, J., G. Decroix, and C. Sors. 1971. [Tuberculosis due to Mycobacterium africanum in Black
African in the Paris area]. Rev Tuberc Pneumol (Paris). 35:430-6.
Grosset, J. 1971. Georges Canetti (1911-1971). Bull Int Union Tuberc. 46:7-8.
Boulahbal, F., and J. Grosset. 1971. Use of pyridinium cetyl bromide as a transport medium for
tuberculous sputum. Preliminary study. Arch Inst Pasteur Alger. 49:51-9.
Year 1970
Canetti, G., J. Grosset, and M. Le Lirzin. 1970. [Sterilization of tuberculous lesions under
chemotherapy in humans. Main report]. Bull Int Union Tuberc. 43:347-59.
Larbaoui, D., P. Chaulet, J. Grosset, K. Abderrahim, and H. Ait-Mesbah. 1970. The efficiency of
methods of diagnosing pulmonary tuberculosis: an investigation in a chest clinic in Algiers. Tubercle.
51:403-11.
De Beco, O., F. Boulahbal, and J. Grosset. 1970. [Incidence of the bovine bacillus in human
tuberculosis at Algiers in 1969]. Arch Inst Pasteur Alger. 48:93-101.
Grosset, J., and M. Benhassine. 1970. La thiacetazone (Tb-1): donnees experimentales et cliniques
recentes (recent experimental and clinical data) Adv Tuberc Research 17:108-153.
Larbaoui, D., P. Chaulet, J. Grosset, K. Abderrahim, N. Oussedik, C. Coucke, and L. Benabdallah.
1970. [Intermittent treatment of "intractable chronic tuberculosis" by combined rifampicin-ethambutol:
preliminary results of a controlled survey made in Algeria]. Rev Tuberc Pneumol (Paris). 34:559-66.
18
Larbaoui, D., P. Chaulet, J. Grosset, K. Abderrahim, and A. Zirout. 1970. [Controlled study of a biweekly treatment with isoniazid and ethionamide]. Bull Int Union Tuberc. 43:282-8.
Year 1969
Grosset J., A. Ait Khaled, et B Ould Rouis. 1969. Etude bactériologique de 249 méningites
tuberculeuses observées à Alger de 1964 à 1968. Arch. Inst. Pasteur d'Algérie. 47: 27-41.
Grosset J.1969. La résistance, écueil majeur du traitement de la tuberculose pulmonaire. Med. Hyg.,
895: 1444-1446.
Year 1968
Chaulet, P., K. Abderrahim, J. Grosset, and D. Larbaoui. 1968. Clinical experience in Algeria of
intermittent treatment of pulmonary tuberculosis with isoniazid and streptomycin twice-weekly.
Tubercle. 49:Suppl:81-2.
Chaulet, P., M. Boulahbal, and J. Grosset. 1968. Acquired resistance to antibiotics of the tuberculosis
bacillus in the Algiers area from 1963 to 1967. Importance and epidemiologic significance. Rev Tuberc
Pneumol (Paris). 32:542-51.
Grosset, J., M. Benhassine, and L. Mokhtari. 1968. [Trial B.C.G. vaccination without previous
tuberculin test in an Algiers outpatient clinic]. Rev Tuberc Pneumol (Paris). 32:551-60.
Grosset, J., K. Abderrahim, P. Chaulet, and D. Larbaoui. 1968. [Results of bi-weekly treatment with
isoniazid and streptomycin in 135 cases of pulmonary tuberculisis, in Algiers]. Bull Int Union Tuberc.
41:325-30.
Grosset, J., F. Rodrigues, M. Benhassine, P. Chaulet, and D. Larbaoui. 1968. Sensitivity to
thiacetazone of strains of Mycobacterium tuberculosis isolated in Algiers: practical deductions.
Tubercle. 49:Suppl:46-8.
Seror, J., and J. Grosset. 1968. [A propos of a case of mesenteric adenitis caused by Eberth's
bacillus]. Ann Chir. 22:629-31.
Galtier M., J. Grosset et P. Oriol. 1968. Fréquence de Mycobacterium bovis dans les tuberculoses
extra-pulmonaires à Alger; Arch. InStitut Pasteur d'Algérie. 46: 160-161.
Year 1967
Grumbach, F., G. Canetti, J. Grosset, and M. le Lirzin. 1967. Late results of long-term intermittent
chemotherapy of advanced, murine tuberculosis: limits of the murine model. Tubercle. 48:11-26.
Chaulet, P., D. Larbaoui, J. Grosset, and K. Abderrahim. 1967. Intermittent chemotherapy with
isoniazid and streptomycin in Algiers. Tubercle. 48:128-36.
Grosset, J., and M. Benhassine. 1967. [Antibiotic primary resistance of mycobacterium tuberculosis in
hospitals in Algeria (1964-1966)]. Rev Tuberc Pneumol (Paris). 31:475-90.
Year 1965
Grosset J. and R. Neel. 1965. Enquête sur la frequence de la resistance primaire et de la resistance
acquise du bacille tuberculeux aux antibiotiques en Algerie. Bull. Inst. Nat. Sante Publique (Alger). 3:
30.
Chaulet P., D. Larbaoui, J. Grosset, M. Drif, and P. Levi-Valensi. 1965. Les consequences
therapeutiques de la resistance du bacille de Koch aux antibiotiques chez les malades deja traites.
Bull. Inst. Nat. Sante Publique (Alger). 3: 32.
19
Larbaoui D., P. Chaulet, J. Grosset, M. Drif, and P. Levi-Valensi.1965.Consequences pratiques de la
resistance primaire aux antibiotiques. Bull. Inst. Nat. Sante Publique (Alger). 3: 36.
Chaulet P. P. Levi-Valensi, D. Larbaoui, and J. Grosset. 1965. Le traitement intermittent de la
tuberculose pulmonaire. Premiers resultats d’une enquête limitee. Bull. Inst. Nat. Sante Publique
(Alger). 3: 40
Grosset J., P. Chaulet, D Larbaoui, G. Hadjadj, M. Drif and P. Levi-Valensi. 1965. Frequence et
consequence de la resistance du bacille de Koch aux antibiotiques. Enquête sur la region algeroise. J.
Med. Maroc. 1: 51-58
Year 1964
Grumbach F., G. Canetti, and J. Grosset. 1964. Further experiments on long-term chemotherapy of
advanced murine tuberculosis with emphasis on intermittent regimens. Tubercle, Lond. 45: 125-135.
Canetti G., B. Kreis, R. Thibier, J. Grosset, and J. Gluszyk. 1964. Frequence et caractere de la
resistance primaire dans 2144 cas de tuberculose pulmonaire non encore traitee provenant de
diverses regions de France (premier rapport du Centre d’Etudes sur la Resistance Primaire). Rev.
Tuberc.et Pneum. 28: 1115-1158.
Canetti G., N. Rist, and J. Grosset. 1964. Primary drug resistance in tuberculosis. Amer. Rev. Resp.
Dis. 90: 792-799.
Grosset J., P. Chaulet, D Larbaoui, G. Hadjadj, M. Drif and P. Levi-Valensi. 1964. Etude de la
resistance aux antibiotiques chez les tuberculeux pulmonaires recemment hospitalises au C.H.U.
d’Alger. Arch. Inst Pasteur d’Algerie. 42: 3-13.
Canetti G., J. Grosset, and A. Cetrangolo. 1964. Une simplification technique de la methode des
proportions pour test de sensibilite du bacille tuberculeux: l’emploi d’une anse de platine. Arch. Inst
Pasteur d’Algerie. 42: 14-37.
Year 1963
Lepeuple A., R. Thibier, J.N. Vivien, G. Canetti, and J. Grosset. 1963. Identification des sources de
contagion dans quelques cas de resistance primaire tuberculeuse. Rev. Tuberc.et Pneum. 27: 53-66.
Canetti G., N. Rist, and J. Grosset. 1963. Mesure de la sensibilite du bacille tuberculeux aux drogues
antibacillaires par la methode des proportions. Rev. Tuberc.et Pneum. 27: 217-272.
Thibier R., A. Lepeuple, J.N. Vivien and J. Grosset. 1963. Resultats de la chimiotherapie chez 221
malades atteints de tuberculose pulmonaire a bacilles initialement sensibles aux antibiotiques majeurs
(recul de 2 a 5 ans). Rev. Tuberc.et Pneum. 27: 541.
Vivien J.N., R. Thibier, A. Lepeuple, G. Canetti, and J. Grosset. 1963. Le dosage systematique de
l’isonizide actif dans le serum sanguin. Rev. Tuberc.et Pneum. 1103-1118.
Canetti G., F. Grumbach, and J. Grosset. 1963. Long-term two-stage chemotherapy of advanced
experimental murine tuberculosis with intermittent regime during the second stage. Tubercle, Lond.
44: 236.
Year 1962
Grosset J., and G. Canetti. 1962. Teneur des souches sauvages de Mycobacterium tuberculosis en
variants resistants aux antibiotiques mineurs. Ann. Inst. Pasteur. 103:163-183.
Vivien J.N., R. Thibier, A. Lepeuple and J. Grosset. 1962. La precision de la mesure pratique du taux
serique d’isoniazide actif par la methode microbiologique de diffusion verticale. Rev. Tuberc.et Pneum.
26: 978-988.
20
Year 1961
Canetti G., and J. Grosset. 1961. Teneur des souches sauvages de Mycobacterium tuberculosis en
variants resistants a l’isoniazide et en variants resistants a la streptomycine sur milieu de loewensteinJensen. Ann. Inst. Pasteur. 101:28-46.
Grosset J. and G. Canetti. 1961. Difference de teneur des souches de Mycobacterium tuberculosis en
variants et J resistants a la streptomycine selon la variete de streptomycine et le milieu de culture
employe. Ann. Inst. Pasteur. 101:234-252.
Grosset J. 1961. Donnees anatomiques et bacteriologiques sur l’aspergillome survenant chez des
tuberculeux. Bull. soc. Fr. Mycol. Med. 3: 4.
Grosset J. L’inactivation de l’isoniazide chez le rat. 1961. Proc. XVIth Intern. Tuberc. Conf. Toronto
Sep. 1961. Excerpta Medica. 44: 548-552.
Year 1960
Grumbach F., J. Grosset, and G. Canetti. 1960. L’inactivation de l’isoniazide chez le rat. Son
incidence sur les resultats de la chimiotherapie de la tuberculose de cette espece. Ann. Inst. Pasteur.
98: 642-656.
Grosset J. and G. Canetti. 1960. Donnees complementaires sur le dosage de l’isoniazide actif du
serum sanguin par la methode de diffusion verticale. Dosage en presence de PAS. Rev. Tuberc.et
Pneum. 24: 633-647.
Canetti G., F. Grumbach, and J. Grosset.1960. Studies of bacillary populations in experimental
tuberculosis of mice treated by INH. Amer. Rev. Resp. Dis. 82 : 295-313.
Thibier R., G. Canetti, A. Lepeuple, J. Grosset, and J.N. Vivien. 1960. tuberculoses pulmonaires a
bacilles resistants chez des malades non encore traites. Rev. Tuberc.et Pneum. 24: 831-868.
Lepeuple A., R. Thibier, J.N. Vivien, J. Grosset, and G. Canetti. 1960. un cas de transmission de
bacilles de Koch d’un sujet tuberculeux a un sujet gueri de tuberculose pulmonaire. Rev. Tuberc.et
Pneum. 24: 1312-1321.
Year 1959
Lepeuple A., R. Thibier, J.N. Vivien, J. Grosset, and G. Canetti. 1959. Les troubles psychiques
provoques par l’isoniazide. Leur relation avec les antecedents psychiques et le taux sanguin
d’isoniazide libre des malades. Rev. Tuberc.et Pneum. 23: 214-230.
Year 1958
Grosset J., G. Canetti, R. Thibier, J.N.Vivien, A. Lepeuple, and A. Saenz.1958. Effet compare du
P.A.S. buccal et du P.A.S. intra-veineux sur le taux d’isoniazide actif dans le serum sanguin. Rev.
Tuberc. 22: 202-207.
Vivien J.N., R. Thibier, J. Grosset, and A. Lepeuple. 1958. Resultats precoces de l’isonazido-therapie
en fonction du taux d’isoniazide actif dans le serum (une etude de 100 cas). Rev. Tuberc. 22: 208222.
Canetti G., J. Bretey, A. Saenz, and J. Grosset. 1958. Effet d’un traitement precoce par l’isoniazide
sur l’immunite engendree chez un cobaye par und dose de B.C.G. standard faible. Donneees
supplementaires sur le pouvoir vaccinant du B.C.G. isoniazido-resistant. Ann. Inst. Pasteur. 95 : 262271.
21
Canetti G., and J. Grosset. 1958. Frequence des fistules adeno-bronchites post-primaires dans 397
cas de tuberculose pulmonaire de l’adulte traitee par exerese. Discussion de leur role phtisiogene.
Rev. Tuberc. 22: 653-657.
Canetti G., and J. Grosset. 1958. L’influence du taux maximum d’INH libre du serum sur la structure
des souches isoniazido-resistantes apparaissant au cours de l’isoniazido-therapie )une etude portant
sur des cas d’exerese). Rev. Tuberc. 22: 778-806.
Grosset J., and G. Canetti. 1958. La methode de diffusion verticale. Sa valeur dans le dosage de
l’isoniazide libre du serum. Rev. Tuberc. 22: 1077-1085.
Year 1957
Grosset J., F. Grumbach, and G. Canetti. 1957. Une modification des methodes de dosage
biologique de l’isoniazide dans le serum sanguin. Resultats dans 53 cas. Ann. Inst. Pasteur. 92 ; 752759.
Year 1956
Canetti G., and J. Grosset. 1956. Positivation tardive des cultures de bacilles tuberculeux; ses
rapports avec l’isoniazido-resistance. Rev. Tuberc. 20 : 1053
Conference Abstracts
>100, not listed
Chapters, Review Articles:
EL Nuermberger, WR. Bishai, and JH. Grosset. 2004. Latent Tuberculosis Infection. Seminars in
Respiratory and Critical Care Medicine
Grosset J., C. Truffot-Pernot, E. Cambau. 2000. Bacteriology of tuberculosis.
In Tuberculosis, a comprehensive international approach, second edition, revised and expanded. L.B.
REICHMAN, E.S. HERSHFIELD. Marcel Dekker Ed. 2000, p. 157-185.
Lounis N., C. Truffot-Pernot, B. Ji, J. Grosset. 1999
Pharmacokinetics and animal studies of rifapentine in tuberculosis.
Drugs of today 1999; 35, suppl. D: 17-27.
Trystram D., J. Robert, C. Truffot-Pernot, V. Jarlier, J. Grosset. 1999.
Infections à mycobactéries et résistance aux antituberculeux.
In Bulletin Epidemiologique Annuel. Epidemiologie des maladies infectieuses en France. Situation en
1997 et tendance évolutive récente. Réseau National de Santé Publique ed. Saint Maurice, France.
pp 119-121.
Grosset J. and B. Ji. 1998. Experimental Chemotherapy of Mycobacterial Diseases. P. 51- 97.
In Mycobacteria II Chemotherapy. Edited by PRJ Gangadharam and PA Jenkins. Chapman & Hall
Medical Microbiology Series.New York, 1998.
Wyplosz B., Ch. Truffot-Pernot, J. Robert, V. Jarlier, J. Grosset. 1997.
Bacteriologie de la tuberculose et des infections à mycobactéries atypiques.
Rev. Mal. Respir. 14: 5S33-5S48.
Grosset J. H., R.J. O'Brien. 1997.
Advances in tuberculosis preventive therapy.
Seminars in Respiratory and Critical Care Medicine. 18 : 449-457.
Grosset J..Histoire de la tuberculose. 1997. Dossier Option Hôpital "L'isolement", Roussel et Diamant
Hôpital, janvier: 17-23.
22
Grosset J. 1993. Fréquence et gravité actuelles de la résistance de Mycobacterium tuberculosis aux
antibiotiques.Annales de l'Institut Pasteur/Actualités, , 4 : 196-202.
Truffot-Pernot C., J. Grosset, B. Gicquel, V. Jarlier, F. Doucet-Populaire.1992.
Bactériologie de la tuberculose et des infections à mycobactéries atypiques.
Editions Techniques. Encycl. Méd. Chir. (Paris, France). Pneumologie, 6019 A 34, 12 p.
Grosset J..What is the role of B.C.G. in this changing World? 1992
Everyday Problems in Respiratory Medicine; 1.
Grosset J., C. Truffot-Pernot. 1988. Etat actuel de la résistance de Mycobacterium tuberculosis aux
antibiotiques. La lettre de l'infectiologue. 10, 369-377.
Grosset J. Bacteriologic basis of short-course chemotherapy for tuberculosis. 1980. Clinics in Chest
Medicine. Vol. 1. No.2: 231-241
Grosset J. and M. Benhassine. 1970. La thiacetazone (Tb1): donnees experimentales et cliniques
recentes. Adv. Tuberc. Res. 17: 108-153.
Canetti G., S. Froman, J. Grosset, P Hauduroy, M. Langerova, H.T. Mahler, G. Meissner, D. A.
Mitchison and L. Sula. 1963. Mycobacteria: laboratory methods for testing drug sensitivity and
resistance. Bull. Wld. Hlth. Org. 29: 565-578.
Vivien J.N., and J. Grosset. 1961. Le taux d’isoniazide actif dans le serum sanguin. Adv. Tuberc. Res.
11: 45-121.
Chapters in Conference Proceedings:
Truffot-Pernot Ch., J. Robert, V. Jarlier, and J. Grosset. 1998. Diagnostic bactériologique de la
tuberculose. In Outils d'investigation microbiologique en réanimation. B. Dupont, F. Gouin, V. Jarlier,
M. Wolff. Arnette Editeur. pp. 127-142
Grosset J..L'histoire du traitement de la tuberculose. 1998.
In Les médicaments de la tuberculose chez l'enfant. G. Pons, D. Gendrel, J. Grosset. Pp. 73-84.
Collection Recherche Clinique Thérapeutique, Springer-Verlag France, Paris.
Truffot-Pernot C., J. Robert, V. Jarlier, J. Grosset. 1998. Le diagnostic bactériologique de la tuberculose.
In Les médicaments de la tuberculose chez l'enfant. G. Pons, D. Gendrel, J. Grosset. pp. 55-72.
Collection Recherche Clinique Thérapeutique, Springer-Verlag France, Paris.
Grosset J., C. Truffot-Pernot, V. Schwoebel, B. Decludt, S. Haeghebaert. 1996.
Evolution de la résistance de Mycobacterium tuberculosis aux antibiotiques.
In Prévention des infections nosocomiales en chirurgie. Prévention contre les germes multirésistants.
J. Grosset, M. Kitzis, N. Lambert, M. Sinegre, Edit. pp. 215-227, Arnette Ed.
Grosset J., B. Ji, Ch. Truffot-Pernot, N. Lounis. 1995.
Mycobactéries, place de l'amikacine : de nouveaux schémas thérapeutiques.
La Lettre de l'Infectiologue, numéro hors série: 19-21.
Thabaut A., J.L. Avril, C. Bebear, E. Bergogne-Berezin, I. Boucot, D. Chiche, R. Cluzel, V. Jarlier, J.
Grosset, J.F. Lemeland, M. Meyran, H. Monteil, C. Morel, M.H. Nicolas, A. Philippon, M.E. Reverdy,
J. Sirot. 1995. Evolution de la sensibilité des bacilles à Gram négatif à la ceftazidime et à trois autres
bêta-lactamines en milieu hospitalier de 1989 à 1993.
Méd. Mal. Inf. 25 : 6-19.
Groupe ECRIR.
La PCR est-elle un outil diagnostique pertinent de la tuberculose en 1994 ?
La Lettre de l'Infectiologue 1994 ; IX : 107.
Feur E., J. Grosset. 1994.
23
Usage courant de la vaccination antituberculeuse et des tests tuberculiniques auprès des enfants du
Val-de-Marne, à l'entrée à l'école primaire.
Bull.Epid.Hebdo. n° 42: 197-198.
Grosset J., Ch. Truffot-Pernot, V. Jarlier. 1993.
Caractéristiques bactériologiques des mycobactéries du complexe aviaire.
La Lettre de l'Infectiologue, numéro hors-série, 11-14.
Grosset J., C. Truffot-Pernot, H. Boisvert, V. Lalande. 1991.
Qu'est-ce que les mycobactéries atypiques ?
Méd. Mal. Infect. 21 special : 7-15.
Grosset, J. and S. Leventis. 1983. Adverse effects of rifampin. Rev Infect Dis. 5: S440-50.
Sors C. and J. Grosset. 1972. Le traitement de la tuberculose pulmonaire en 1972, compte-tenu des
donnees acquises. Entretiens de Bichat, 1972, vol. therapeutique, p. 251-254.
Chaulet P., D. Larbaoui, J. Grosset, N Oussedik, L. Mazouni, and F. Boulahbal. 1971. Le traitement
de relais de la tuberculose pulmonaire par l’administration intermittente de rifampicine et d’ethambutol.
XXIth Conf Inter. Union against Tuberculosis. Moscou, Juillet 1971. Acta Tuberc Pneum. Belg. 62:
316-317.
Canetti G. with E. Bernard, P. Coletsos, G. Daddi, Ch Gernez-Rieux, J. Grosset and B. Kreis. 1959.
Aspect pratique du probleme de la resistance du bacille de Koch aux medications antibacillaires. Le
poumon et le cœur. N.10, 1035.
Educational Activities
1. Internal teaching
- Between 1966 and 1970, all lectures on Bacteriology and Virology for the students in Medicine and in
Pharmacy, Faculty of Medicine and Pharmacy, Algiers, Algeria. More than 50 hours per year
- Between 1970 and 1999, lectures on bacteriology for the Medical students, Faculty of Medicine PitieSalpetriere (25 hours per year)
- Each year, several lectures for Infectious Diseases and Antibiotic Therapy, Faculty of Medicine PitieSalpetriere (10 hours per year)
- Each year, 1-week lectures on mycobacteria for the training course of specialists in Medical Biology,
Paris
2. External teaching
2.1. WHO / International Training Course (5th) in Epidemiology and Control of Tuberculosis (in
French): Bacteriologic diagnosis of tuberculosis. Rome, March 30-April 9, 1965
2.2. WHO / International Training Course (6th) in Epidemipology and Control of Tuberculosis (in
French): Field Control of Tuberculosis. Tunis, April 1966
2.3. WHO / International Training Course in Epidemipology and Control of Tuberculosis: The treatment
of tuberculosis. Prague, June 9-15, 1970.
2.4. WHO / Assisted Regional Tuberculosis Training Course, Kyose, Tokyo, Japan: the use of
bacteriology for the Control of Tuberculosis:
- July 18-29. 1971
- September 9-19, 1973
- July 21-31, 1974
- September 8-13, 1975
- July 25-August 4, 1978
- July 14-19, 1980
- July 5-12, 1981
2.5. The first joint THELEP-Sasakawa Memorial Health Foundation Workshop on experimental
chemotherapy of leprosy. Osaka, Japan. November 11-20, 1986. (Organized and directed by J.
Grosset, B Ji, T. Ito).
24
2.6. School of Public Health, Rennes, France. Lecture on treatment of tuberculosis. Nov.19, 1970;
May 6. 1971; Nov.5, 1971. Participation in the workshop Tuberculosis and Public Health, April 17-21,
1972.
2.7. Mission for the Ministry of Foreign Affairs (France) to Guinea-Conakry, from May 25 to June 16,
1978: Basic Teaching on Medical Bacteriology, Vaccinations, Essential Antibiotics, Organisation of the
Chemotherapy for Tuberculosis.
Mentoring (pre and post doctoral Trainees)
>50, not listed
Organizational Activities
Scientific Advisory Panels/Boards/Steering Committes
Member of the Management Board (Conseil de Gestion)
Pitie-Salpetriere School of Medicine
Jan 77- Dec 79
Member of the Scientific Board
Paris VI University
Jan 77- Dec 79
Chairman of the Committee for Control of Hospital Infection
Pitie-Salpetriere Hospital
1979-1999
Chairman of the WHO/THELEP Steering Committee, Geneva,
Chemotherapy of leprosy
1983-1992
Chairman of the WHO THEMYC Steering Committee
Chemotherapy of mycobacterial diseases
1993-1995
Chairman of the WHO Advisory group on Buruli Ucer
1999- present
Member of the Scientific Advisory Committee (SAC)
2000- 2001
Global Alliance against tuberculosis (GATB), renewed 2001- present
Society Memberships:
American society for Microbiology (ASM)
International Union against Tuberculosis and Lung Disease
International Leprosy Association.
Societe Francaise de microbiologie
Societe Francaise de la tuberculose et des Maladies Respiratoires
Honors and Awards
Laureate of National Academy of Medicine, Paris, Prix Berthe PEAN, 1966
Gardner Middlebrook Award, Salt Lake City, May 21, 2002
Additional Information
Personal statement of research and research objectives
Tuberculosis was still a leading cause of death in industrialized countries when I started my
medical studies. Despite the tremendous progress made during the past half-century, M. tuberculosis
still infects over 1.7 billion people, causes disease in over 8 million people every year, and kills more
than 2 million people every year. Since the beginning of my professional life I have been involved in
research to improve the treatment of tuberculosis and prevent the development of drug resistance.
During the past 45 years, I have participated in the development of nearly all new drug regimens used
for tuberculosis and a number of other mycobacterial diseases, namely leprosy, M.avium complex
infection, and M. ulcerans infection (Buruli ulcer). At present, my primary interest remains in the use of
25
the mouse model to investigate the efficacy of new drugs and new drug combinations in human
diseases caused by mycobacteria.
Any investigator involved in the study of antituberculous chemotherapy must grapple with 2
phenomena unique to the pathogenesis and treatment of tuberculosis. The first is a propensity for the
initial infection to evolve under the pressure of host immunity into a paucibacillary latent state which
may reactivate into clinical disease at a later point in time. The second is a capacity for persistence of
a small bacillary population in a state of unresponsiveness to antimicrobials to which they are
genotypically susceptible. The mechanisms by which the bacteria transition to and survive in the latent
and persistent states are unknown. Therefore, the identification of bacterial factors involved in both
states would be extremely beneficial for the both the preventive and the curative therapy of
tuberculosis. The genomics revolution has provided the tools and techniques necessary to begin to
identify those bacterial factors regulating the adaptive response. My collaboration with Dr. William.
Bishai, a recognized expert in the field of mycobacterial genetics and pathogenesis offers a unique
opportunity to address these crucial issues.
Keywords
Tuberculosis, leprosy, M.avium complex infection, Buruli ulcer, mouse model, drug resistance, latency,
persistence, Mycobacterium tuberculosis, M.leprae, M. ulcerans, gene regulation.